Needham analyst Chad Messer last week maintained a Buy rating on the stock with a $7 price target (202% upside potential). “We believe GNCA is undervalued versus peer neo-antigen cancer vaccine companies despite Genocea’s early clinical stage,” Messer wrote in a note to investors. “W...
Stock of Beltsville, Md., Biotechnology Firm Rises after Cancer Research.Stefanova, Kristina
We convene experts across the world to share the latest thinking and research at hosted events, such as the McKinsey Cancer Congress Series at the American Society for Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) conferences. In addition, we routinely attend key ...
C.A. holds stock options in Provista and Y-TRAP and serves in the Scientific Advisory Board of the Komen Foundation. N.U.L. receives or has received research support paid directly to the Institution from Genentech, Pfizer, Merck, and Seattle Genetics. N.U.L. has served as a consultant ...
(NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Aster Insights, a bioinformatics company with the most advanced, direct-patient, lifetime-consented clinicogenomics data to accelerate oncolog...
, Oct. 8, 2024 /PRNewswire/ -- GWI research commissioned by Roche (SIX: RO, ROG; OTCQX: RHHBY) and carried out across 12 countries in Latin America and Europe has revealed that half of those polled have either limited or no awareness...
Neither YQ nor FZ have received any royalties and do not have intellectual property, patent, or stock holdings with vaccine or drug companies. Other authors declare no competing interests.Additional information Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in ...
Smith is not alone. Cancer patients are 2.5 times more likely to file for bankruptcy after they are diagnosed, according to the Fred Hutchinson Cancer Research Center, based in Seattle. Among the financial pain points are the high tab for therapies, out-of-pocket insurance costs and loss of ...
Rivière from New York's MSKCC, and Stanley Riddell, Philip Greenberg, and Michael Jensen from the Hutchin- son Cancer Center/Seattle Children's Hospital, came together to form their own company, Juno Pharmaceuti- cals, using private investment and publicly traded stock to fund their research...
PM Dechow,AP Hutton,RG Sloan - 《Contemporary Accounting Research》 被引量: 1047发表: 2000年 The Economic Case for Private Equity (and Some Concerns) -- pdf of Keynote Slides Presented at the Harvard Business School Centennial Conference on Private Equity, New York City, Feb. 13, 2007; the...